Life Sciences Companies Adopt Veeva Nitro to Eliminate the Burden of Custom Data Warehouse Development and Maintenance
Veeva Systems (NYSE:VEEV) today announced that life sciences companies are adopting Veeva Nitro to accelerate their data warehouse projects and deliver faster insights to the business. Veeva Nitro is a life sciences-specific commercial data warehouse that eliminates the time and effort of custom data warehouses and provides a foundation for artificial intelligence (AI) and advanced analytics. In half a year since the product’s availability, six companies have selected Veeva Nitro, including Karyopharm Therapeutics (NASDAQ:KPTI) and MannKind Corporation (NASDAQ:MNKD), with both customers live and using the product in under five months.
With a fast-growing oncology business and a new therapy coming to market, Karyopharm Therapeutics needed to bring together a variety of data sets – including Veeva CRM and claims data – to empower field teams with the right information to reach the right stakeholders.
“Veeva Nitro removed many of the challenges in implementing a data warehouse and accelerated our ability to provide the field with useful, actionable insights,” said Jason Magyar, sr. director, enterprise applications, Karyopharm Therapeutics. “In just a few months, we gained a host of capabilities with Veeva Commercial Cloud and Veeva Nitro that other solutions sometimes take years to deliver, if ever. We now have a solid foundation for growth and to drive intelligent customer engagement.”
Veeva Nitro provides an industry-specific data model and standard integrations that unify a company’s most important data sources, including prescription, sales, formulary, and claims data. Data is automatically updated when data structures or sources change, eliminating the significant effort typically required to maintain a custom-built data warehouse.
Analytics-ready, Veeva Nitro also gives companies the flexibility to use the business intelligence and AI tools of their choice. With seamless integration to Veeva CRM MyInsights, any time data changes in Veeva Nitro it automatically syncs in Veeva CRM MyInsights. Now customers can deliver tailored insights to field teams right at the point of execution on any mobile device.
“Veeva Nitro allowed us to build and configure our data warehouse quickly and efficiently,” said Andrew Zepfel, associate director, sales operations, MannKind Corporation, a biopharmaceutical company that provides therapeutic products for patients with diseases such as diabetes. “Veeva Nitro will allow us to keep up with changes in the business as they happen and give us a foundation for advanced analytics.”
“For decades the life sciences industry has been held back by custom data warehouses that are inflexible and out-of-date, so they fail to deliver the right insights to the business,” said Andy Fuchs, vice president, Veeva Nitro. “Veeva Nitro finally gives companies a pre-built commercial data warehouse that is fast to deploy and delivers always current insights at speeds that were never before possible.”
Veeva Nitro is available today in North America and Japan and planned for availability in Europe in mid-2019.
To learn more about Veeva Nitro and how it can help build the foundation for intelligent engagement, watch this video from Matt Wallach, Veeva president.
For more on Veeva Nitro, visit: veeva.com/eu/Nitro
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 700 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2018. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2019 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
IDEMIA Provides NOS with eSIM Management Solutions18.4.2019 10:49:00 CEST | Pressemelding
At the occasion of the launch of the first ever eSIM (embedded SIM) service on the Portuguese market, NOS today introduces with IDEMIA an eSIM subscription management commercial service for the consumer market, based on a physical voucher approach and future evolution towards a digital voucher. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005321/en/ (Photo: IDEMIA) As a major actor in the telecom field, IDEMIA is at the forefront of the digital revolution and is committed to bringing protected and convenient experiences to mobile operator customers. IDEMIA will be providing NOS its eSIM management solutions that will provide instant digital connectivity that allows users to connect any electronic device straight out-of-the-box and link multiple devices to the same mobile subscription. eSIM offers a streamlined user experience when it comes to managing cellular connectivity for Enterprises. According to ABI Research,
AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines for AqVida’s Cancer-fighting Paclitaxel Injectable Finished Dosage Formulation18.4.2019 10:00:00 CEST | Pressemelding
Phyton Biotech, a German/North American Plant Cell Fermentation (PCF®) technology company, and AqVida, a German oncology Finished Dosage Formulation (FDF) manufacturer, are pleased to announce today that they have received European approval from the EDQM (European Directorate of Quality Medicines) for AqVida’s paclitaxel injectable FDF. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005161/en/ Phyton Biotech is the world’s leading manufacturer of paclitaxel active pharmaceutical ingredient (API), utilizing its prorprietary PCF® technology process. Under the strategic partnership with AqVida, Phyton Biotech will be the exclusive supplier of paclitaxel API for AqVida’s Taxol generic formulation, which is produced in AqVida’s new state-of-the-art injectable manufacturing facility located in Dassow, Germany. AqVida’s ultramodern robotic manufacturing line, designed for filling cytotoxic injectables, will be utilized to pro
Racketeering Lawsuit Filed by Boies Schiller Flexner LLP Alleges Czech Oligarch Defrauds US Hedge Fund and Former Partner Out of Over $1 Billion18.4.2019 07:41:00 CEST | Pressemelding
New York hedge fund, Kingstown Capital Management L.P, and other plaintiffs filed a lawsuit on 10 April 2019 in the Southern District of New York against Radovan Vitek, a Czech real estate mogul with business interests throughout Europe, whose fortune Forbes magazine estimates at $3.5 billion. Represented by litigation powerhouse Boies Schiller Flexner LLP, the hedge fund Kingstown Capital Management L.P and Czech investment firm Investhold Ltd allege that Vitek ran an elaborate criminal enterprise that defrauded the plaintiffs out of more than US $1 billion. According to the complaint, Berlin’s largest commercial real estate landlord, Vitek engaged in racketeering activity including wire fraud, mail fraud, money laundering, and other crimes and amassed his wealth at the expense of the plaintiffs, according to the complaint. His commercial interests span multiple jurisdictions including the Czech Republic, Switzerland, Luxembourg, Germany, Croatia and UK. The complaint alleges that Vit
MHI Thermal Systems Develops Demonstration Unit of the World’s First Small-Capacity Residential Air-Conditioner Adopting the Low-GWP R454C Refrigerant18.4.2019 07:21:00 CEST | Pressemelding
Premiering for the first time in the world, Mitsubishi Heavy Industries Thermal Systems, Ltd., a Group company of Mitsubishi Heavy Industries, Ltd. (MHI) (TOKYO: 7011), is adopting R454C, a refrigerant with an extremely low global warming potential (GWP), in a 1-horsepower (HP) class residential air-conditioner. The conventional shortcomings of the R454C,for example; inferior heat exchanger performance attributable to it being a mixed refrigerant have been overcome through the use of proprietary technology that optimize the heat exchanger’s flow volume and other measures. The company has already developed a demonstration unit of the residential air-conditioner featuring R454C and preparations are underway towards mass production with an eye on an initial launch into the European market, where environmental regulations are particularly stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005241/en/ Residential type
Hologic Receives European CE Mark for ThinPrep® Genesis Processor, an Automated Cytology Slide and Molecular Sample System18.4.2019 07:00:00 CEST | Pressemelding
Hologic, Inc. (Nasdaq: HOLX) announced today that the ThinPrep® Genesis processor for cytology slide and molecular test preparation has received a CE IVD mark in Europe. The system features increased automation capabilities, together with ergonomic and chain of custody benefits, compared to older instruments. Most importantly, the instrument will prepare slides for cytology as well as aliquot samples for molecular testing, reducing manual sample handling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005130/en/ ThinPrep Genesis processor (Photo: Business Wire) The Genesis processor is the latest extension of the ThinPrep portfolio, which revolutionized and increased the accuracy of cervical cancer screening with the first liquid-based Pap test in 1996. Hologic launched an updated ThinPrep® 2000 processor in 2017 and received FDA approval in 2018 for the ThinPrep® Integrated Imager, which guides cytotechnologists to ar
Ipsen Completes Acquisition of Clementia Pharmaceuticals18.4.2019 05:00:00 CEST | Pressemelding
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and Clementia Pharmaceuticals (NASDAQ: CMTA) today announced the closing of Ipsen’s acquisition of Clementia following approval of the arrangement by Clementia shareholders and the Quebec Superior Court. Pursuant to the arrangement, Clementia shareholders will receive US$25.00 per share in cash upfront and one contingent value right (CVR) per share entitling them to receive US$6.00 per CVR upon the U.S. Food and Drug Administration's (FDA) acceptance of the regulatory filing for palovarotene for the treatment of multiple osteochondromas (MO). Clementia’s key late-stage clinical asset palovarotene is an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of two rare bone disorders, fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), and other diseases. The palovarotene regulatory submission for the prevention of heterotopic ossification (HO) in patients with FOP in the U.S.